Instrument Inactif

Autres langues EnteroMedics Inc Nasdaq

Actions

US29365M2089

Autres langues

14/09	Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
28/08	Vyome Holdings, Inc. Announces CFO Changes
28/08	Vyome Holdings, Inc. Appoints Jerry Leonard as Principal Financial Officer and Principal Accounting Officer, Effective September 1, 2026
25/08	Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
12/08	Vyome Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
01/07	Vyome Receives China Patent for Besifloxacin Acne Gel
01/07	Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
28/05	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
12/05	Vyome Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Vyome strikes deal with Impetis Biosciences, opening a ~$57B market opportunity
12/05	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
22/04	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
22/04	Vyome Holdings, Inc. Presents Transformational VT-1953 Phase 2 Clinical Study Data
06/04	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
06/04	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
26/03	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
18/03	Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
24/02	Livechain completes acquisition of senior, secured debt of Humanyze
18/02	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
11/02	Vyome files for VT-1953 orphan drug status, furthers strategic focus on VT-1953 program over the next 6 months
11/02	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
02/02	Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results
02/02	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
27/01	Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
22/12	Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company